Dr. Michael L. Dougan, MD, PHD
Gastroenterology (Gastroenterology Physician)
Massachusetts General Hospital, 55 Fruit Street
Boston, MA 02114
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 188
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Harvard Medical School
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MA license L-247885
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 188
- Services billed
- 413
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 114 | 73 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 73 | 63 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 49 | 45 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 35 | 35 |
| Established patient office or other outpatient visit, 40-54 minutes | 28 | 28 |
| Biopsy of lower large bowel using a flexible endoscope | 27 | 24 |
| Biopsy of large bowel using a flexible endoscope | 21 | 19 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 20 | 20 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 17 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Boston, MA | 60 |
| Budesonide Ec (budesonide) Other prescribers in Boston, MA | 23 |
| Creon (lipase/protease/amylase) Other prescribers in Boston, MA | 19 |
| Budesonide Dr (budesonide) Other prescribers in Boston, MA | 19 |
| Mesalamine Other prescribers in Boston, MA | 19 |
| Pantoprazole Sodium Other prescribers in Boston, MA | 16 |
| Dupixent Pen (dupilumab) Other prescribers in Boston, MA | 15 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Boston, MA | 14 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Boston, MA | 13 |
| Cholestyramine (cholestyramine (with sugar)) Other prescribers in Boston, MA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $10,030 in total to this clinician.
| Gilead Sciences, Inc. | $10,030 |
|---|
| Consulting Fee | $10,030 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Aug 19, 2025 | Consulting FeeCompany’s description;4092260;SAP;10953405 | $4,250 |
| Gilead Sciences, Inc. Oct 14, 2025 | Consulting FeeCompany’s description;4158316;SAP;10953405 | $3,230 |
| Gilead Sciences, Inc. Dec 9, 2025 | Consulting FeeCompany’s description;4225933;SAP;10953405 | $2,550 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $5,866 in research payments for these studies, mostly to the institutions running them.
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.